We're excited to have you on board

Hey there, biotech income trader! Looking at this Eli Lilly chart, you can see a remarkable story - a stock that's exploded from $700 to $825 on massive volume, driven by the weight-loss drug revolution. Notice those "VOL BUY" signals and the bullish EMA alignment? At $816.76, LLY represents both an enormous opportunity and a significant risk. This creates the perfect setup for the Pharma Parachute strategy - designed to generate income from biotech volatility while protecting against the sect

Hey there, biotech income trader! Looking at this Eli Lilly chart, you can see a remarkable story - a stock that's exploded from $700 to $825 on massive volume, driven by the weight-loss drug revolution. Notice those "VOL BUY" signals and the bullish EMA alignment? At $816.76, LLY represents both an enormous opportunity and a significant risk. This creates the perfect setup for the Pharma Parachute strategy - designed to generate income from biotech volatility while protecting against the sector's inherent risks. Why Eli Lilly's Pattern Creates Perfect Pharma Parachute Conditions LLY's chart shows classic biotech momentum characteristics: Explosive breakout from $700 to $825+ (18% move in weeks) Volume-driven momentum suggesting institutional accumulation Clear support levels established during the climb High implied volatility creating rich option premiums Binary risk from drug trials, FDA decisions, and competitive threats This creates an ideal environment for harvesting premium while managing biotech-specific risks. How the Pharma Parachute Works (Eli Lilly Example) With LLY at $816.76 after a massive run, here's your pharma parachute setup: The Protected Income Trinity: 1. Covered Call Income Layer: OWN 100 shares ($81,676 position) SELL $850 call for $15 ($1,500 credit) Cap upside at $850 while collecting substantial premium 2. Protective Put Parachute: BUY $780 put for $18 ($1,800) Protects against biotech-style crashes below $780 3. Cash-Secured Put for Accumulation: SELL $750 put for $12 ($1,200 credit) Generate income with willingness to buy more at $750 Net Strategy Cost: $1,100 (protective put cost minus premiums collected) with significant downside protection The Biotech Volatility Advantage Pharmaceutical stocks like LLY are uniquely positioned due to: Blockbuster drugs (Mounjaro, Zepbound) driving explosive revenue growth $50+ billion obesity drug market potential Patent protection providing multi-year revenue visibility Pipeline drugs creating ongoing catalyst events But also: FDA risks, trial failures, competitive threats The Pharma Parachute captures the upside while managing these binary risks. Three Biotech Scenarios LLY continues to $850-900: Your shares appreciate $33-83 per share ($3,300-8,300), covered call limits gains at $850 but you collect $1,500 premium. Total profit: $3,300-4,800 with ongoing premium collection. LLY consolidates $780-850: Your covered call generates $1,500 monthly income while protective put maintains value. Roll positions monthly for continued income generation with protection intact. LLY crashes on negative news (trial failure, competition): Your $780 put limits losses below that level, while you've collected $2,700 in premiums. Maximum loss from $816 entry: $3,376 (4.1%) versus potentially 20-30% in a biotech selloff. Managing Your Eli Lilly Parachute ⚠️ Clinical trial announcements - Biotech stocks gap violently on trial results ⚠️ FDA decisions - Regulatory approvals/rejections trigger explosive moves ⚠️ Competitive threats - Novo Nordisk, Amgen developments affect LLY sentiment ⚠️ Earnings volatility - Guidance changes can move stock 10%+ overnight Perfect Pharma Parachute Candidates LLY - As shown, blockbuster drug momentum with significant volatility NVO - Novo Nordisk for competing obesity drug exposure AMGN - Amgen for diversified biotech with stable cash flows XBI - Biotech ETF for sector-wide volatility harvesting Weekend Pharma Analysis Monitor clinical trial calendars and FDA decision dates Track obesity drug sales data and market share trends Review patent expiration timelines and pipeline developments Check competitive landscape and new drug approvals Assess valuation metrics relative to growth projections The Risk-Managed Biotech Approach The chart shows LLY's explosive move, but biotech history is filled with similar charts that reversed violently on negative news. The Pharma Parachute strategy acknowledges this reality: Income Generation: $1,500-3,000 monthly from covered calls and cash-secured puts  Downside Protection: Hard stop at $780 (4% below current) via protective puts  Accumulation Strategy: Willingness to add shares at $750 if assigned  Upside Participation: Full participation to $850, then capped but profitable Remember, while LLY's obesity drugs are revolutionary, biotech stocks can decline 30-50% on single news events. The Pharma Parachute ensures you're generating income from the volatility while having a literal "parachute" if the story changes. Another signal just hit from this new tool. Mani just added it to the community and it's already performing. Fresh indicator. Fresh signals. Fresh opportunities. Get Riptide Access Trade the innovation, protect the downside! Regards, FindBetterTrades Trading Strategy Guides © 2025 – Unsubscribe